Lifeboat Foundation: Safeguarding Humanity
Toggle light / dark theme

Blog

Category: biotech/medical

The full antiaging rejuvenation toolkit of the next few decades will consist of a range of different treatments, each targeting a different type of molecular damage in cells and tissues. Fightaging predicts the likely order of arrival of some of these therapies, based on what is presently going on in research, funding, and for-profit development.

1) Clearance of Senescent Cells

Everon Biosciences, Oisin Biotechnologies, SIWA Therapeutics, and UNITY Biotechnology are all forging ahead with various different approaches to the selective destruction of senescent cells. No doubt many groups within established Big Pharma entities are also taking a stab at this, more quietly, and with less press attention. UNITY Biotechnology has raised more than $100 million to date, demonstrating that there is broad enthusiasm for this approach to the treatment of aging and age-related disease.

Read more

A brand new type of HIV vaccine will move onto phase II clinical trials in 2017, after phase I trials showed that it was safe to use in humans.

The potential new vaccine will be tested on 600 people in North America, to see how well it can prevent them from getting the virus.

Before we get too excited, the phase I trials were only set up to show that the vaccine was tolerated well by the human body — they didn’t demonstrate if it actually works as a preventative treatment.

Read more

Scientists hoping to get a glimpse of molecules that control brain activity have devised a new probe that allows them to image these molecules without using any chemical or radioactive labels.

Currently the gold standard approach to imaging molecules in the brain is to tag them with radioactive probes. However, these probes offer low resolution and they can’t easily be used to watch dynamic events, says Alan Jasanoff, an MIT professor of biological engineering.

Jasanoff and his colleagues have developed new sensors consisting of proteins designed to detect a particular target, which causes them to dilate blood vessels in the immediate area. This produces a change in blood flow that can be imaged with magnetic resonance imaging (MRI) or other imaging techniques.

Read more

Great.

Research published in Acta Neuropathologica, identified alterations in a protein known as ATRX in human brain tumours; researchers might also be able to target microRNAs directly, altering their levels to make cancer cells less likely to form tumours.

A recent study suggests that two recently discovered genetic differences between brain cancer cells and normal tissue cells could offer clues to tumour behaviour and potential new targets for therapy.

Published in Acta Neuropathologica, the study identified alterations in a protein known as ATRX in human brain tumours that arise as part of a genetically inherited condition known as neurofibromatosis type 1 (NF1). The disorder, marked initially by benign tumours on nerves, often leads to brain cancer, and although most NF1-related malignancies are nonaggressive, a fraction are “high-grade” and difficult to treat, experts say.

Read more

A huge discovery has just been made about Parkinson’s disease that scientists may have been looking for answers in the wrong place all along. Scientists have found that there is a strong correlation between symptoms of Parkinson’s and bacteria in the gut, not the brain, based on examinations of mice.

Parkinson’s disease is the second most common debilitating brain disorder in the world after Alzheimer’s. It is a neurodegenerative disease that involves a type of protein that builds up around brain cells and then causes the patient to lose motor function. Naturally, scientists had been looking at the brain for answers in dealing with it, but a new study finds that perhaps the answer was in the gut bacteria all along, according to an Axial Biotherapeutics statement.

The finding could lead to a new generation of probiotics that are far more sophisticated than typical brands currently available to the public.

Read more

I know this is 2 days old; however, glad I came across it. As Gene Circuitry & Living systems in general are truly advancing more quickly in the recent year than I have seen over the past decade.

The real question is with AI, 3D/ 4D synbio printing, Gene/ Cell Circuitry; which areas of medicine will continue to existing in the next 15 years?

A Brock University research team has created a tool that can potentially be used in a future computer that will be made out of DNA.

Chemist Feng Li and graduate student Xiaolong Yang, formal postdoctoral fellow Yanan Tang and undergraduate student Sarah Traynor have devised a strategy that “helps simplify the design of DNA circuits that may eventually be used in a DNA computer,” says Li.

The team’s research was recently featured in the Journal of the American Chemical Society.

Read more

That’s the bad news.

The good news is that mental health professionals have smarter tools than ever before, with artificial intelligence-related technology coming to the forefront to help diagnose patients, often with much greater accuracy than humans.

A new study published in the journal Suicide and Life-Threatening Behavior, for example, showed that machine learning is up to 93 percent accurate in identifying a suicidal person. The research, led by John Pestian, a professor at Cincinnati Children’s Hospital Medical Center, involved 379 teenage patients from three area hospitals.

Read more